Kazia has released its FY19 Annual Report. Notable highlights are listed below.
- GDC-0084 has completed a Phase I clinical trial with Genentech and is now undergoing a Phase II clinical trial in glioblastoma, sponsored by Kazia, focusing on newly diagnosed patients.
- Cantrixil is currently in a Phase I clinical trial which has established a MTD of 5 mg/kg and has shown pleasing efficacy signals in the first phase of this trial.
- $6,174,832 funds generated from capital raise and sale of shares during FY19, substantially funding our operations for the year
To read the full report, click here.
About Kazia Therapeutics (ASX: KZA)
Kazia Therapeutics is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. Headquartered
in Sydney, Australia, Kazia Therapeutics collaborates with leading scientists, clinicians, and investors around the world.